The Asia Pacific Gabapentin Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).
Gabapentin still remains one of the most prescribed medicines to treat chronic pain. Although chronic pain frequently develops due to an illness or injury, it is a distinct condition in and of itself and not merely a symptom of other illnesses. As a result, chronic pain has a distinct taxonomy and medical description. Recurrent tension-type headaches are one of the most prevalent symptomatic chronic diseases, affecting 1.9 billion people worldwide and contributing to the growing burden of chronic pain.
Neck and low back pain have continuously been the primary causes of disability, accounting for the majority of years lived with disability, with other chronic pain diseases making significant appearances in the top 10. An episode of shingles can result in postherpetic neuralgia. According to the CDC, approximately 10% to 18% of people with shingles develop postherpetic neuralgia. The FDA has only approved using gabapentin under the trade name Gralise to manage postherpetic neuralgia (PHN). An extended-release medication called Horizant (gabapentin enacarbil) is prescribed to treat adults with PHN and restless legs syndrome.
Chronic pain is one of the most important healthcare concerns in the region as the proportion of the aging population and the frequency of associated illnesses rises. Additionally, notwithstanding the Southeast Asian nations' achievements in sustainable health care and forward-thinking economic growth, controlling epilepsy is still difficult because of the huge cultural, racial, and political variety among its population. This can be considered a management gap, diagnostic accuracy & facilities gaps, medical & surgical treatment gaps, and stigma reduction gaps. The burden of these health issues is increasing the demand for gabapentin drugs significantly. Therefore, in the coming years, the region presents lucrative growth opportunities for the gabapentin market.
The China market dominated the Asia Pacific Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $203.6 million by 2028. The Japan market is estimated to grow a CAGR of 4.6% during (2022 - 2028). Additionally, The India market would experience a CAGR of 5.9% during (2022 - 2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Gabapentin Market is Projected to reach USD 2.6 Billion by 2028, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
By Application
By Dosage Form
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
